AARP Eye Center
)
The Inflation Reduction Act (IRA) of 2022 includes many provisions designed to address high prescription drug prices and related out-of-pocket costs. One of the most notable changes allows Medicare to negotiate the prices of certain high-cost prescription drugs, which is expected to save Medicare…
Quiet Policy Change Could Lead to Substantial Savings for People in Medicare Prescription Drug Plans
Millions of older Americans are already benefitting from a new law passed in 2022 that includes several provisions to help reduce out-of-pocket costs and the high prescription drug prices driving them. One of the most notable and publicized changes is a redesign of the Medicare Part D benefit that…
Medicare just announced the first set of Part D drugs that will be subject to negotiation, and the resulting negotiated prices will become available in 2026.
A new law that addresses high prescription drug prices and out-of-pocket costs will help improve the affordability of insulin for millions of diabetic Medicare beneficiaries, and new research sheds light on its potential impact.
High and growing prescription drug prices will eventually affect all Americans in some way. Congress is currently considering proposals that will permit Medicare to negotiate with drug companies, as well as discourage price increases that exceed inflation.
Despite the myriad of financial challenges facing patients and all Americans, many brand name drug companies have already increased the prices of their products in 2022.
A new type of prescription drug for stroke prevention for adults with atrial fibrillation quickly replaced the existing standard treatment—even before evidence emerged to support the switch.
Fifteen years ago, President George W. Bush signed the Medicare Prescription Drug, Improvement, and Modernization Act which, among other things, created Medicare Part D to cover outpatient prescription drugs. Today, more than 40 million Americans are enrolled in Medicare Part D prescription drug…
Turing Pharmaceuticals recently faced intense public criticism after the company bought a 62-year-old drug and increased its price by 5,000 percent. Turing’s unusually outspoken chief executive officer, Martin Shkreli, strongly defended the decision, even going so far as to argue that the new price…
Lately you may have noticed a growing number of commercials filled with people happily touting the benefits of their new joints. Experts expect such procedures to become increasingly popular as the active boomer population continues to age. However, the commercials typically gloss over the fact…